Clinical Rheumatology

, Volume 33, Issue 1, pp 137–139

Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases

  • C. Sengler
  • M. Niewerth
  • T. Kallinich
  • A. Nimtz-Talaska
  • M. Haller
  • H.-I. Huppertz
  • K. Minden
Brief Report

DOI: 10.1007/s10067-013-2435-8

Cite this article as:
Sengler, C., Niewerth, M., Kallinich, T. et al. Clin Rheumatol (2014) 33: 137. doi:10.1007/s10067-013-2435-8
  • 135 Downloads

Abstract

The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented—38 % under treatment with biologicals—of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.

Keywords

Children Disease activity Flare H1N1 influenza vaccination Rheumatic disease 

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • C. Sengler
    • 1
  • M. Niewerth
    • 1
  • T. Kallinich
    • 2
  • A. Nimtz-Talaska
    • 3
  • M. Haller
    • 4
  • H.-I. Huppertz
    • 5
  • K. Minden
    • 1
  1. 1.Epidemiology UnitGerman Rheumatism Research Centre Berlin, Leibniz InstituteBerlinGermany
  2. 2.Children’s University Hospital, Department of Pediatric Pneumology and ImmunologyCharité—Universitätsmedizin BerlinBerlinGermany
  3. 3.Pediatrician/Pediatric Rheumatologist in Private PracticeFrankfurt/OderGermany
  4. 4.Pediatrician/Pediatric Rheumatologist in Private PracticeGundelfingenGermany
  5. 5.Klinikum Bremen MitteBremenGermany

Personalised recommendations